Aquestive Therapeutics (AQST) Other Operating Expenses (2017 - 2026)

Aquestive Therapeutics' Other Operating Expenses history runs 10 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 5.01% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $18.4 million (up 7.22% YoY), while the FY2025 annual figure was $18.6 million, up 3.82% from the prior year.
• Other Operating Expenses was $3.5 million for Q1 2026 at Aquestive Therapeutics, down from $5.8 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $6.6 million in Q2 2023 to a low of $3.5 million in Q1 2026.
• Historically, Other Operating Expenses has averaged $4.7 million across 5 years, with a median of $4.6 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Other Operating Expenses surged 57.61% in 2022, then tumbled 31.6% in 2024.
• A 5-year view of Other Operating Expenses shows it stood at $5.3 million in 2022, then declined by 11.8% to $4.7 million in 2023, then decreased by 3.4% to $4.5 million in 2024, then increased by 29.12% to $5.8 million in 2025, then sank by 40.56% to $3.5 million in 2026.
• The last three Other Operating Expenses figures came in at $3.5 million (Q1 2026), $5.8 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.